# Oklahoma Health Care Authority

**Drug Utilization Review Board**
**(DUR Board)**
**Meeting – April 13, 2022 @ 4:00pm**
at the
Oklahoma Health Care Authority (OHCA)
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

***NOTE:*** ***The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.***

## AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call to Order**

A. Roll Call - Dr. Wilcox

**DUR Board Members:**

| | |
|---|---|
| Dr. Stephen Anderson – | participating in person |
| Dr. Jennifer de los Angeles – | participating in person |
| Ms. Jennifer Boyett – | participating in person |
| Dr. Megan Hanner – | participating in person |
| Dr. Lynn Mitchell – | participating in person |
| Dr. John Muchmore – | participating in person |
| Dr. Lee Muñoz – | participating in person |
| Dr. James Osborne – | participating in person |

**Viewing Access Only via Zoom:**

Please register for the meeting at:
https://zoom.us/webinar/register/WN_73z8ERX7Sv-KeQGP3GVqPg
After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:
Dial: +1-602-753-0140 or +1-669-219-2599
Webinar ID: 952 7560 1667
Passcode: 69395211

**Public Comment for Meeting:**

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the Speaker Registration Form. Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
   A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**
   A. February 9, 2022 DUR Board Meeting Minutes
   B. February 9, 2022 DUR Board Recommendations Memorandum
   C. Correspondence

Items to be presented by Dr. O'Halloran, Dr. Wilson, Dr. Muchmore, Chairman:

4. **Update on Medication Coverage Authorization Unit/Spring 2022 Pipeline Update – See Appendix B**
   A. Pharmacy Helpdesk Activity for February 2022
   B. Medication Coverage Activity for February 2022
   C. Pharmacy Helpdesk Activity for March 2022
   D. Medication Coverage Activity for March 2022
   E. Spring Pipeline Update

Items to be presented by Dr. Smith, Dr. Muchmore, Chairman:

5. **Medication Therapy Management Program (MTM) Calendar Year 2021 Review – See Appendix C**
   A. Background
   B. Workflow
   C. Results
   D. Case Study
   E. Summary

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

6. **Action Item – Vote to Prior Authorize Elepsia™ XR [Levetiracetam Extended-Release (ER) Tablet] and Eprontia™ (Topiramate Oral Solution) – See Appendix D**
   A. Market News and Updates
   B. Elepsia™ XR (Levetiracetam ER) Product Summary
   C. Eprontia™ (Topiramate Oral Solution) Product Summary
   D. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

7. **Action Item – Vote to Prior Authorize Winlevi® (Clascoterone 1% Cream) – See Appendix E**
   A. Market News and Updates
   B. Winlevi® (Clascoterone 1% Cream) Product Summary
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

8. **Action Item – Vote to Prior Authorize Dojolvi® (Triheptanoin) – See Appendix F**
   A. Market News and Updates
   B. Dojolvi® (Triheptanoin) Product Summary
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

9. **Action Item – Vote to Prior Authorize Qulipta™ (Atogepant) and Trudhesa™ (Dihydroergotamine Nasal Spray) and Update the Approval Criteria for the Anti-Migraine Medications – See Appendix G**
   A. Market News and Updates
   B. Qulipta™ (Atogepant) Product Summary
   C. Trudhesa™ (Dihydroergotamine Nasal Spray) Product Summary
   D. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

10. **Action Item – Vote to Prior Authorize Erwinase® (Crisantaspase), Erwinaze® (Asparaginase *Erwinia Chrysanthemi*), Oncaspar® (Pegaspargase), Rylaze™ [Asparaginase *Erwinia Chrysanthemi* (Recombinant)-rywn], and Scemblix® (Asciminib) and Update the Approval Criteria for the Leukemia Medications – See Appendix H**
    A. Market News and Updates
    B. Product Summaries
    C. College of Pharmacy Recommendations

Items to be presented by Dr. Ratterman, Dr. Muchmore, Chairman:

11. **Action Item – Annual Review of Hemophilia Medications – See Appendix I**
    A. Current Prior Authorization Criteria

B. Utilization of Hemophilia Medications
C. Prior Authorization of Hemophilia Medications
D. Market News and Updates
E. Hemophilia A with Inhibitor Treatment
F. Oklahoma Health Care Authority Recommendations
G. Utilization Details of Hemophilia Medications

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

**12. Annual Review of Lymphoma Medications and 30-Day Notice to Prior Authorize Zynlonta™ (Loncastuximab Tesirine-lply) – See Appendix J**

A. Introduction
B. Current Prior Authorization Criteria
C. Utilization of Lymphoma Medications
D. Prior Authorization of Lymphoma Medications
E. Market News and Updates
F. Zynlonta® (Loncastuximab Tesirine-lply) Product Summary
G. College of Pharmacy Recommendations
H. Utilization Details of Lymphoma Medications

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

**13. Annual Review of Lutathera® (Lutetium Lu-177 Dotatate) and Vitrakvi® (Larotrectinib) – See Appendix K**

A. Introduction
B. Current Prior Authorization Criteria
C. Utilization of Lutathera® (Lutetium Lu-177 Dotatate) and Vitrakvi® (Larotrectinib)
D. Prior Authorization of Lutathera® (Lutetium Lu-177 Dotatate) and Vitrakvi® (Larotrectinib)
E. Market News and Updates
F. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

**14. Annual Review of Growth Hormone Products and 30-Day Notice to Prior Authorize Skytrofa® (Lonapegsomatropin-tcgd) and Voxzogo™ (Vosoritide) – See Appendix L**

A. Current Prior Authorization Criteria
B. Utilization of Growth Hormone Products
C. Prior Authorization of Growth Hormone Products
D. Market News and Updates
E. Skytrofa® (Lonapegsomatropin-tcgd) Product Summary
F. Voxzogo™ (Vosoritide) Product Summary
G. College of Pharmacy Recommendations
H. Utilization Details of Growth Hormone Products

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

15. **Annual Review of Granulocyte Colony-Stimulating Factors (G-CSFs) and 30-Day Notice to Prior Authorize Releuko™ (Filgrastim-ayow) – See Appendix M**
    A. Current Prior Authorization Criteria
    B. Utilization of G-CSFs
    C. Prior Authorization of G-CSFs
    D. Market News and Updates
    E. College of Pharmacy Recommendations
    F. Utilization Details of G-CSFs

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

16. **Annual Review of Anti-Parasitic Medications and 30-Day Notice to Prior Authorize Lampit® (Nifurtimox) – See Appendix N**
    A. Current Prior Authorization Criteria
    B. Utilization of Anti-Parasitic Medications
    C. Prior Authorization of Anti-Parasitic Medications
    D. Market News and Updates
    E. Lampit® (Nifurtimox) Product Summary
    F. College of Pharmacy Recommendations
    G. Utilization Details of Anti-Parasitic Medications

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

17. **Annual Review of Systemic Antifungal Medications and 30-Day Notice to Prior Authorize Brexafemme® (Ibrexafungerp) – See Appendix O**
    A. Current Prior Authorization Criteria
    B. Utilization of Systemic Antifungal Medications
    C. Prior Authorization of Systemic Antifungal Medications
    D. Market News and Updates
    E. Brexafemme® (Ibrexafungerp) Product Summary
    F. College of Pharmacy Recommendations
    G. Utilization Details of Systemic Antifungal Medications

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

18. **Annual Review of Multiple Sclerosis (MS) Medications and 30-Day Notice to Prior Authorize Ponvory™ (Ponesimod) – See Appendix P**
    A. Current Prior Authorization Criteria
    B. Utilization of MS Medications
    C. Prior Authorization of MS Medications
    D. Market News and Updates
    E. Ponvory™ (Ponesimod) Product Summary
    F. College of Pharmacy Recommendations
    G. Utilization Details of MS Medications

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

19. **U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix Q**

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

20. **Future Business* (Upcoming Product and Class Reviews)**
    A. Anti-Diabetic Medications
    B. Heart Failure Medications
    C. Lung Cancer Medications
    D. Muscular Dystrophy Medications

    *Future product and class reviews subject to change.

21. **Adjournment**

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.